Search This Blog

Wednesday, October 2, 2019

Leg amputees feel and use nerve-stimulating leg prosthesis as a real limb

A European consortium led by ETH Zurich and SensArs Neuroprosthetics reports that tiny electrodes implanted in a patients’ thigh nerve allow them to feel natural sensations of touch and movement from a prosthesis. Amputees can then walk freely while thinking about activities other than controlling the device. The details of the work were published in Science Translational Medicine and represent a multidisciplinary collaboration among several European institutions.
Djurica Resanovic, one of the volunteers, says, “The first time that I felt my leg, my foot, it was very interesting, like my own leg, after several years.” Wearing a blindfold and earplugs, Resanovic could tell where the foot was being touched, or how much the knee was flexed. “I recognized when they touched thumb, heel or foot, anywhere else.”
Machine and nervous system connected
A sensorized insole is placed under the prosthetic foot. The signals from the insole and prosthetic knee sensors are translated in impulses of current, the language of the human , which are delivered to the residual peripheral nerve through tiny electrodes implanted transversally into the nerve itself. Then, the signals from the residual nerves are conveyed to the brain, which is able to perceive what happens at the prosthesis and to adjust the walking accordingly. The machine and the body are connected. Regaining limb awareness allows the subjects to feel obstacles underfoot and to avoid falls.
“We developed the first leg with feelings for highly disabled, above-knee amputees, which enabled them to surpass unexpected obstacles without falling, or to climb stairs much faster. These two tasks are extremely difficult, if even possible, for amputees wearing commercial prostheses,” said Stanisa Raspopovic, professor at ETH Zurich.
Amputees feel the prosthesis as a real limb
Leg amputees, while walking, do not trust the prosthesis and rely too much on the healthy leg, reducing mobility. The prosthesis, not being connected with the brain, doesn’t feel as a part of their body.
Brain activity measurements and psychophysical tests revealed that the neuroprosthesis is perceived as an extension of the body, as a real limb. The connection between the machine and nerve is fundamental to achieve this.
“You don’t need to concentrate to walk, you can look forward and step, you don’t need to look where your leg will fall.” says Djurica Resanovic, volunteer in the study. “The bionic leg integrated with the residual of amputees enables the brain to accept it as the continuation of the natural leg, and this is essential for higher confidence of the users, and a future widespread of such technology,” Raspopovic said.
“An investigation longer than three months, with more subjects, and with in-home assessments should be executed to provide more robust data to draw clinically significant conclusions about an improvement of the health and quality of life of patients,” says Francesco Petrini.

Explore further
Feeling legs again improves amputees’ health

More information: F.M. Petrini el al., “Enhancing functional abilities and cognitive integration of the lower limb prosthesis,” Science Translational Medicine (2019). stm.sciencemag.org/lookup/doi/ … scitranslmed.aaw3163

Reneuron’s reinvention falters

More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.
In February data from three patients treated with Reneuron’s retinitis pigmentosa stem cell candidate raised hopes that the group might finally have a decent asset. Now, findings in five more patients have given the company a reality check.
As well as showing less impressive efficacy, two subjects suffered procedure-related vision loss. Reneuron’s chief executive, Olav Hellebø, told Vantage that patients with the disorder, which eventually causes blindness, would be willing to take this risk. Still, the company’s shares fell as much as 22% today, and its hopes of finding a partner look to have taken a blow.
Too good to be true?
One problem, Mr Hellebø argued, was that the previous data had been seen as “too good to be true”: three patients initially receiving Reneuron’s human retinal progenitor cells (hRPCs) showed a mean 23-letter improvement from baseline on the ETDRS chart, a measure of visual acuity, after one to two months’ follow-up.
To put this into context, Sanofi and Regeneron’s age-related macular degeneration blockbuster, Eylea, has been linked with 8-11-letter improvements.
Those early results with the hRPCs, which came from the phase II portion of a phase I/II trial, have helped Reneuron’s stock rocket by around 300% over the course of 2019. But the latest data make the project look average.
In total, 10 patients have been treated in the phase II part of the trial; they received subretinal implantation of hRPCs in one eye, while the other remained untreated. Today Reneuron reported data on eight of these patients, the other two having not yet reached 30 days’ follow-up.
Two of the eight experienced procedure-related vision loss. The chief executive noted that this was down to the surgery rather than the cells themselves, and that the company hoped to be able to reduce the risk of this adverse event in future, for example by excluding patients with very damaged retinas at baseline.
But he argued that, for a serious disease like retinitis pigmentosa, doctors and most patients would accept this risk.
Even if this proves to be the case the latest efficacy data with the hRPCs look much less impressive than those previously reported. At three months, the latest timepoint at which data from all eight patients are available, the mean improvement in visual acuity was 6.1 letters in the treated eye.
Mr Hellebø blamed the two patients with vision loss, who he said “lost a lot of letters”, for dragging the result down. Excluding these two subjects gave a 17.8-letter mean improvement over baseline.
More to lose, less to gain
Still, this result was flattered by the first three patients enrolled; the second three-patient cohort showed gains of just 5-11 letters at three months, Reneuron said. A breakdown of patients’ individual responses will be included in a presentation October 12 at the American Academy of Ophthalmology meeting in San Francisco, according to Mr Hellebø.
He added that a drop-off in efficacy had been expected as the second group of patients had less severe vision loss at baseline, so had “more to lose and less to gain”. These patients’ visual acuity had been around 35 letters or more before treatment; below this threshold patients are classified as legally blind. Meanwhile, the first three subjects had baseline levels of 9-32 letters.
As well as raising questions about the hRPCs’ safety and efficacy in a broader patient population, the latest data could give potential partners pause. Mr Hellebø previously told Vantage that Reneuron was looking for collaborators outside Europe (Reneuron eyes a partner with new stem cell data, February 20, 2019).
The group has already signed up Fosun in China, but it must be hoping for a bigger deal, particularly after interest from a US speciality pharma group last year.
Longer-term data from the phase I/II trial could give a better idea of the hRPCs’ true potential, and Reneuron will need to carry out at a larger phase IIb trial, at least, before being able to seek approval for the project, according to the Stifel analyst Christian Glennie.
Perhaps any potential partner will want to wait until after these results come in, to see if things become any clearer.
https://www.evaluate.com/vantage/articles/news/trial-results/reneurons-reinvention-falters

Esmo 2019 makes for a disappointing read-across to biotech

An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
This year’s instalment of Europe’s largest oncology-focused medical congress was another big pharma affair, with the battle between Glaxosmithkline and Astrazeneca/Merck & Co’s Parp inhibitors dominating the agenda. The job for many biotech investors was to figure out the read-across to their favourite stocks.
A case in point was Mirati, which fell 17% on Amgen’s disappointing AMG 510 data, marking a pause in investors’ love affair with Kras targeting. True, the congress coincided with a tough trading period as a whole, but it is incredible that there was only one biotech winner, Seattle Genetics, whose market cap gained a remarkable $2bn over the weekend.
This analysis compares the share prices of Esmo-relevant biopharma companies at market close last Thursday, a day before the most important abstracts were unveiled, and close of play yesterday, formally the meeting’s last day.
Selected Esmo 2019 stocks: biggest risers
Company Price change* Relevant data at Esmo Vantage coverage
Seattle Genetics 18% Enfortumab combo data & tucatinib PD-L1 status moves centre stage in bladder cancer
Hutchison China Meditech 16% Surufatinb in neuroendocrine tumours
Faron 7% Clevegen in colorectal cancer
Merck KGaA 1% Various Esmo 2019 preview – Parps on parade
Glaxosmithkline 1% Zejula in ovarian cancer maintenance Glaxo’s Parp ambitions get a boost
Bristol-Myers Squibb 1% Opdivo in liver cancer & more TMB NSCLC analyses Opdivo could have done better in liver cancer
Deciphera 1% Ripretinib in Invictus GIST study
Roche 0% Imvigor-130 survival readout PD-L1 status moves centre stage in bladder cancer
Incyte 0% Tibsovo in cholangiocarcinoma Targeted bile duct treatment pits Incyte against Agios
Turning Point 0% Reprotrectinib in Ros1-positive cancers
Note: difference between closing prices on Oct 1 and Sep 26.
It might seem strange that Seattle surged on remission rate data in a phase I bladder cancer trial for enfortumab vedotin, a project already filed for accelerated approval, and one that has generated survival data in a highly impressive though uncontrolled phase II trial, EV-201.
But the filing is for second-line use, whereas Seattle’s Esmo data came from the front-line cohort of EV-103, a study combining the nectin-4 inhibitor with Keytruda. In the 45 evaluable PD-L1-positive and negative subjects the confirmed overall remission rate was 71%, with six complete remissions.
Waterfall plot from 1st-line bladder cancer subjects given enfortumab and Keytruda in EV-103. Source: Dr Christopher Hoimes & Esmo.
The potential of immunotherapy in platinum-eligible non-PD-L1 expressing bladder cancer has been thrown into doubt by Roche’s Imvigor-130 trial, from which interim overall survival curves were released for the first time at Esmo. The hint from EV-103 is that checkpoint blockade combined with enfortumab could be the answer.
Seattle was also helped by remission data in colorectal cancer in a trial of tucatinib, acquired through the $614m buyout of Cascadian Therapeutics. The only other significant riser was Hutchison China Meditech, presenting PFS data with surufatinib/sulfatinib in neuroendocrine tumours, though the period also coincided with an offering of stock by its holding company.
Away from big pharma’s immunotherapy trials, targeted treatments like surufatinib had a strong Esmo presence, but biotech came away empty-handed. Deciphera revealed a remarkable PFS advantage for ripretinib in the phase III Invictus trial, while Turning Point presented impressive response rates backing reprotrectinib in Ros1-positive cancers, but both stocks barely crept up.
Selected Esmo 2019 stocks: biggest fallers
Company Price change* Relevant data at Esmo Vantage coverage
G1 Therapeutics (32%) Trilaciclib in TNBC Breast cancer verdict brings G1 down to earth
Calithera (20%) Remission rates with INCB001158
Aravive (17%) AVB-S6-500 in 2L ovarian cancer
Mirati (17%) None Kras springs a leak
Immunomedics (12%) Sacituzumab in 2L bladder cancer PD-L1 status moves centre stage in bladder cancer
Adaptimmune (8%) ADP-A2M4 in synovial sarcoma
Beigene (7%) Tislelizumab in bladder cancer
Astrazeneca (4%) Lynparza in ovarian & prostate cancers Lynparza pushes Parps forward again
Zymeworks (2%) ZW25 in Her2-expressing tumours
Agios (1%) Pemigatinib in cholangiocarcinoma Targeted bile duct treatment pits Incyte against Agios
Amgen (1%) AMG 510 in colorectal & appendiceal tumours Kras springs a leak
Abbvie (1%) Veliparib in ovarian & breast cancers Too little too late for Abbvie and veliparib?
Pfizer (1%) Beacon CRC study Pfizer’s Beacon presents a doublet vs triplet conundrum
Novartis (1%) Kisqali in Moanleesa-3 trial
Lilly (1%) Verzenio in Monarch-2 trial Thyroid results strengthen selpercatinib’s case
Basilea (1%) Derazantinib in cholangiocarcinoma Targeted bile duct treatment pits Incyte against Agios
Pharmamar (1%) Zepsyre in 2/3L mesothelioma Mesothelioma trials contend with super-fast disease progression
Merck & Co 0% Keytruda in (neo)adjuvant TNBC Keynote-522 stokes adjuvant hopes for Keytruda
Clovis 0% Triton2 prostate cancer study Clovis is running out of waves to catch
Note: difference between closing prices on 1 Oct and 26 Sep.
At the opposite end of the scale Mirati crashed 17%, notwithstanding Leerink analysts playing up AMG 510’s disappointing 8% remission rate in colorectal cancer as “opening the door for Mirati to best”. Mirati had tended to trade up on previous reports of Amgen’s data – positive or negative – but the trick did not work this time around.
G1 Therapeutics was the biggest loser, as an Esmo presenter rubbished trilaciclib’s supposed survival benefit in breast cancer. And Immunomedics fell 12%, owing more to a further delay relating to sacituzumab’s complete response letter in breast cancer than to its admittedly positive result in bladder cancer.
As for the big story of Esmo – the three-way battle of Parp inhibitors – this was probably won by Lynparza, thanks to the cannily designed Profound study in prostate cancer, though in the ovarian setting Zejula might have the strongest dataset, vindicating Glaxosmithkline’s $5.1bn purchase of its maker, Tesaro.
Though Clovis was unmoved its Parp, Rubraca, also has an intriguing prostate cancer dataset. The worry is that this is too little, too late for the heavily indebted biotech.
https://www.evaluate.com/vantage/articles/events/conferences/esmo-2019-makes-disappointing-read-across-biotech

Therapists decry layoffs amid skilled nursing reimbursement overhaul

Thousands of physical, occupational and speech therapists have been laid off as skilled-nursing facilities transition to a new payment model that kicked in Tuesday.
Dozens of these therapists have emailed Modern Healthcare saying they have been laid off or had their wages cut as a result of the new patient-driven payment model, which is akin to bundled payments and based on patient assessments and acuity rather than the volume of therapy services. Industry observers expect more fallout as certain providers gamed the system to maximize therapy hours, which are now likely going to be a fraction of what they were under the resource-utilization group model.
One national SNF chain, Genesis HealthCare, is said to have cut its rehabilitation staff by 30%, which translates to more than 4,000 workers, experts said.
Genesis said that is “grossly inaccurate,” claiming that only 585 out of approximately 10,000 rehabilitation employees were affected. Its website lists 14,000 workers.
The company said in a statement that it continues to focus on “clinically appropriate interventions while striving for the best outcomes at the lowest cost.”
“With recent changes in our industry, we have reorganized our therapy gyms, impacting on average less than one person per facility nationally,” Genesis said.
The CMS has said that the patient-driven payment model implementation does not alter patients’ therapy needs, noting that should be the “primary driver of care decisions.”
But several therapists who work in SNFs have alleged that’s not the case.
“Reliant and a few other companies have obviously decided to approach this new payment system financially in a way that does not take into account the patients or their employees. It breaks my heart!” wrote Summer Branch, a speech language pathologist who was laid off by Reliant Rehabilitation on Monday and offered to transition to a per-diem employee.
She said Reliant also expected 95% productivity during her working hours, meaning that time would need to be spent in therapy sessions rather than discussing treatment with patients’ families or completing paperwork.
But Branch is heartened by the stories of many other companies that have approached the new model in the way it was likely meant to be, with a patient-centered approach, she said.
Noblesville, Ind.-based Vertis Therapy has not changed its productivity expectations or laid off any employees, said Jessica Beaudry, vice president of operations.
“What we had as an industry was companies who were overutilizing therapy to get higher reimbursement,” she said. “In the new system, that does not do them any good.”
People should be upset with the companies that are taking advantage of the patient-driven payment model, rather than the model itself, Beaudry added.
“If you are doing the right thing by the patient, everything should be fine,” she said.
Reliant said in a statement that it could not share any details about changes to its day-to-day operations but that its mission remains unchanged—providing the best care to its patients.
Calls and emails to Encore Healthcare regarding its total layoffs were not returned.
The former reimbursement model encouraged potentially unnecessary therapy services, the CMS said, adding that it aims to eliminate that motivation while reducing providers’ administrative burdens. What was intended to be a “budget-neutral” change includes a provision that group and concurrent therapy minutes can account for no more than 25% of the total services provided to the patient.
“There is no question in my mind that therapy hours are going to be a fraction of what they are today,” Gerald Stoll, a vice president with the healthcare division of Hub International Northeast, a global insurance brokerage, told Modern Healthcare last month. “SNFs might not be going after those hip- and knee-replacements anymore. It’s probably not a good time to own a therapy company now. But if you do, you need to adapt and change the business model tremendously.”
In a memo obtained by Modern Healthcare to the therapy staff at a Florida-based SNF, executives said that concurrent and group therapies are “not an option, they are a must.”
The CMS said that the model’s 25% limit on group and concurrent therapy is meant to ensure SNF patients receive quality therapy services and that one-on-one sessions remain the “significant majority.”
The memo went on to say if employees have decreased hours during the week, they may be asked to work on the weekend. Staff may lose their full-time eligibility and benefits if they do not reach 30 hours a week for three consecutive pay periods.
This mandate is similar to memos to therapists at other facilities, according to a Change.org petition to HHS lobbying for patients and therapists to decide the appropriate care plan, rather than follow corporate directives. It has more than 16,000 signatures.
“No one knows or could even understand the depth of the devastation of this,” said Jill Sadler, a physical therapist assistant who was laid off on Oct. 1 by Genesis’ Oak Grove Center, a skilled-nursing home in Waterville, Maine, where she worked 14 years. “It affects way more than the therapists. Our elderly deserve the best at the end of life but are always last for all services.”
The wave of unemployed therapists will likely outweigh the demand for their services, Vertis Therapy’s Beaudry said.
“They will likely struggle for a while,” she said. “It is definitely a very scary thing right now for our industry.”
https://www.modernhealthcare.com/payment/therapists-decry-layoffs-amid-snf-reimbursement-overhaul

Durect gets Jan. FDA panel meeting date

DURECT Corporation (Nasdaq: DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bupivacaine extended-release solution) will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). The meeting is tentatively scheduled for January 16, 2020. The FDA had previously assigned a user fee goal date of December 27, 2019; a new user fee goal date has not been assigned.
DURECT commissioned the advisory services of Dr. Lee S. Simon to lead the Company’s preparation efforts to prepare for the advisory committee meeting. Dr. Simon is a physician and research scientist who served as the FDA’s Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products from 2001 to 2003, and is now a Principal at SDG, LLC, an FDA advisory firm.
“We look forward to a productive discussion with the advisory committee,” stated James E. Brown, President and CEO of DURECT. “If approved, we believe that POSIMIR could help address an important need for new long-acting, non-opioid pain products in the post-operative pain setting.”
https://www.prnewswire.com/news-releases/durect-announces-fda-advisory-committee-meeting-to-review-posimir-for-the-treatment-of-post-surgical-pain-300929450.html

J&J opioid settlement should help return focus to fundamentals: Credit Suisse

Johnson & Johnson (JNJ +1.4%) is the only Dow stock sporting a gain amid today’s broader market rout, after surprising investors by announcing a settlement with two Ohio counties ahead of an upcoming opioid trial.
Credit Suisse’s Matt Miksic reiterates an Outperform rating on JNJ with a $156 price target, saying while the settlement does not clear the company of all potential opioid-related litigation liability, increased clarity on liability should shift focus to the company’s fundamentals, and the latest news is “a solid step” in the right direction.
Miksic says his recently updated analysis of sales and prescription trends for July and August points to $570M upside to its U.S. pharmaceuticals estimates for Q3.
https://seekingalpha.com/news/3503467-j-and-j-opioid-settlement-help-return-focus-fundamentals-analyst-says

Ambulatory Surgery Center Inspections Lag: OIG

Dozens of states, some of them very large, didn’t meet Medicare’s requirement that they survey their ambulatory surgery centers (ASCs) at required intervals to assure they met safety protocols, such as infection control or anesthesia administration, and many facilities went without any state survey for at least 6 years.
That’s the finding of a recent report from the U.S. Department of Health and Human Services’ Office of Inspector General (OIG). The agency took some states to task for not following two rules during fiscal years 2013-2017 — made more imperative now that Medicare and commercial insurers reimburse ASCs for increasingly risky procedures.
The two Medicare rules at issue apply to 3,722 of the 5,603 ASCs that were not surveyed by a Medicare-approved “deeming” agency, such as The Joint Commission, and must be surveyed by their state health agency.
Red ink
The first rule is that the state health agency review at least 25% of the “non-deemed” ASCs annually. The OIG found that 15 states, including California, New Jersey, New York, Nevada, Colorado, Rhode Island, and Wisconsin — which the report highlighted in red ink — surveyed fewer than 25% of its ASCs in 2017. These states had a total of 764 ASCs in 2017. California had the most at 414.
The second rule requires states to inspect all of their non-deemed ASCs at least once every 6 years. Some 28 states failed to meet that second requirement, although 19 states surveyed more than 95%.
Again in red ink, the report singled out four states, with a total of 291 ASCs requiring inspection, showing exceptionally low rates over that 6-year review period: Nevada (48%), Hawaii (64%), North Carolina (72%), and New Jersey (85%). In those states, according to the OIG, 75 ASCs went uninspected by the state for at least 6 years.
Hawaii, Nevada, and New Jersey met neither requirement by large margins, the report said.
The OIG noted that inspections are increasingly important because ASCs are now approved for a growing number of invasive, complex surgeries. To meet Medicare rules, the facilities must pass muster on 14 conditions of participation, such as assuring that a registered nurse is available for emergency treatment for any patient in an ASC, and must track patient health outcomes with quality indicators that identify medical errors and adverse events.
State agencies “play critical roles in ensuring the health and safety of Medicare beneficiaries who receive medical procedures, including invasive surgeries, from ASCs,” and because “periodic surveys are an essential tool for ensuring that ASCs meet the minimum standards for health and safety,” the report said.
Asked for a comment, Kay Tucker of the Ambulatory Surgery Center Association, noted that the study was part of the OIG’s routine work plan. “It did note that, although more improvement is warranted, significant improvement has been made over time,” she said.
The last OIG report on this topic was published in 2002.
Tucker emphasized that while these 3,722 ASCs were not inspected by a Medicare deeming agency, some that weren’t inspected by their states at these intervals may have been by another organization, such as the Accreditation Association for Ambulatory Health Care. She estimated that one-third take that route. Those that do are expected to receive 3-year inspections from agencies other than the state.
ASCs make a decision to go with another accreditation organization because they may “want insights from different entities … or they might simply choose to avoid the additional expense involved in seeking deemed status from one of the accrediting organizations,” Tucker said. It also means they subject themselves to two inspections instead of one, since states are still required to inspect them under Medicare rules.
More and riskier procedures
Not only are ASCs growing in number – Tucker said there are now at least 200 more than in 2017 — surgical procedures that just a few years ago were only performed in an inpatient hospital setting are now moving to ASCs, where patients are discharged in 24 hours. For example, Medicare plans to allow total knee replacements and a half-dozen types of percutaneous cardiovascular interventions to be reimbursed in an ASC setting in 2020, although that policy could change with the agency’s final rule.
Tucker emphasized that this has been a fast-moving trend. In 2015, 2016, and 2017, she said, the Centers for Medicare and Medicaid Services added 38 procedures to the ASC payable list, including spine, vascular, and gynecologic procedures. She said the association wants parity for “all procedures” that Medicare has approved for reimbursement in a hospital outpatient department, so they are approved for payment in an ASC as well.
Two states that responded to questions about the report denied that they were in violation of Medicare rules. New Jersey Department of Health spokeswoman Dawn Thomas disputed the OIG’s findings as “not accurate,” and said that on average, Medicare certified ASCs are inspected every 4 years in that state.
And a spokesman for the California Department of Public Health said that a June 2018 update of the data OIG used for the current report showed that California met all of the federal thresholds, and the report is simply wrong.
Beth LaBouyer, executive director of the California Ambulatory Surgery Center Association, called the report confusing and noted it did not mention that many of California’s 414 non-deemed ASCs are inspected every 3 years by another accreditation agency whose procedures mirror those of a deeming accreditation organization like The Joint Commission.
“I know the deemed survey is significantly more expensive,” she said.
Serious problems found
The inspections are not merely a bureaucratic exercise: states that did conduct them often found problems, some of which posted significant threats to patient safety.
Just over three-fourths of the facilities inspected during 2013-2017 had at least one deficiency and 25% had serious deficiencies. The most common one were lapses in infection control, which made up about 20% of the deficiencies. “Serious deficiencies” are those grave enough to indicate what the report called “pervasive noncompliance” and posing “a serious threat to patient health and safety.”
“These findings underscore the importance of timely surveys so that deficiencies do not go unaddressed even longer,” the report said.
Other report findings:
  • During 2013-2017, complaints were filed on just 4% of ASCs, but the share of those complaints that required an onsite survey, including those considered an “immediate jeopardy” — those likely to cause serious injury, harm, impairment, or death — more than tripled, from 15% to 54%.
  • In general, ASCs “appear to struggle” with infection control requirements. When states did inspect their ASCs, they found more than half were deficient in infection control procedures, such as making sure surgical equipment was properly sanitized.
  • Of the 732 complaints that states received about ASCs during 2013-2017, nearly half were substantiated. They included a finding that the ASC “failed to properly assess patients pre-operatively, did not have medical records for some patients, and did not follow its own procedures.”
  • Of the ASCs inspected, roughly a third had deficiencies in observing pharmaceutical requirements, environmental controls, or patient rights, and some failed to meet all three.
  • For those surveys done by state agencies, the mean number of deficiencies dropped from 2013 to 2017, from 6.1 to 4.2, but that may not mean the facilities were providing safer or higher quality care. “These decreases could reflect improvements in ASC performance and/or changes in how states assessed compliance,” the report said.
Assuring ASC quality is also important because of the increasing sums Medicare pays to them, from $3.4 billion in 2011 to $4.6 billion in 2017.
https://www.medpagetoday.com/publichealthpolicy/healthpolicy/82522